| ADX Energy Ltd (ADX) ORDINARY FULLY PAID |
Energy |
$23 |
HOCH-1 Well Deepened after Encountering Further Gas
|
8 May 2026 8:33AM |
$0.032 |
$0.026 |
fallen by
18.75%
|
|
ADX - Price-sensitive ASX Announcement
Full Release
Key Points
- HOCH-1 well in Upper Austria encountered additional gas intervals.
- Well deepened to a measured depth of 1619 metres.
- Six additional gas sand intervals found, each 1 to 2 metres thick.
- Wireline logging program scheduled to confirm results.
- HOCH-1 targets Miocene sandstones in the Hall Formation.
- Prospective resource potential estimated between 8.0 and 17.3 BCF.
- ADX Energy Ltd holds a 50% economic interest in the project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$172 |
Update - Notification of buy-back - BBT
|
8 May 2026 8:31AM |
$0.185 |
$0.165 |
fallen by
10.81%
|
|
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$57,738 |
Stockholder Proposal
|
8 May 2026 8:30AM |
$98.340 |
$103.410 |
risen by
5.16%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,890 |
Net Tangible Asset Backing
|
8 May 2026 8:29AM |
$4.390 |
$4.560 |
risen by
3.87%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$62 |
Amplia and ANZGOG announce Ovarian Cancer Study
|
8 May 2026 8:29AM |
$0.135 |
$0.120 |
fallen by
11.11%
|
|
ATX - Price-sensitive ASX Announcement
Full Release
Key Points
- Amplia Therapeutics Limited and ANZGOG have announced a new clinical study on ovarian cancer.
- The study will evaluate the safety of narmafotinib combined with standard chemotherapy in high-grade serous ovarian cancer patients.
- The trial is named PRROSE and will be conducted in Australia and New Zealand.
- The study focuses on patients who did not respond to standard platinum-based chemotherapy.
- Approximately 15-20 patients are expected to enroll in this trial.
- The study aims to explore if adding narmafotinib can increase surgical success rates.
- Biomarker analysis will be conducted to understand narmafotinib's mechanism of action.
- Dr. Chris Burns from Amplia highlighted the potential of FAK inhibitors in treating ovarian cancer.
- ANZGOG's collaborative network supports the study, which may change clinical practices in gynecological cancers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Schoolblazer Limited (SBZ) ORDINARY FULLY PAID |
Industrials |
$86 |
Half Year Results and Corporate Update
|
8 May 2026 8:28AM |
$0.200 |
$0.165 |
fallen by
17.50%
|
|
SBZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Schoolblazer Group achieved $55.4 million in revenue for the first half of the fiscal year.
- The company's revenue is significantly seasonal, with two-thirds generated in the second half.
- Geopolitical issues and increased freight rates impacted sales and margins.
- The group added 28 new contracted schools, bolstering future revenue expectations.
- The company expects FY26 revenue between $190-200 million.
- Schoolblazer Group signed a term sheet with an Australian Bank for refinancing.
- Global CEO Matthew Easter relocated to Australia to lead local growth.
- Schoolblazer Limited realized $2.7 million from its investment portfolio.
- Phillip Christopher was appointed as Group Finance Director.
- The group is progressing towards its FY27 EBITDA target of $25 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ama Group Limited (AMA) ORDINARY FULLY PAID |
Industrials |
$229 |
Notification of buy-back - AMA
|
8 May 2026 8:28AM |
$0.570 |
$0.475 |
fallen by
16.67%
|
|
| Ama Group Limited (AMA) ORDINARY FULLY PAID |
Industrials |
$229 |
On-Market Share Buy-Back Announcement
|
8 May 2026 8:27AM |
$0.570 |
$0.475 |
fallen by
16.67%
|
|
AMA - Price-sensitive ASX Announcement
Full Release
Key Points
- On-market share buy-back of up to 47,826,141 ordinary shares
- Buy-back within '10/12 limit' of Corporations Act 2001
- No shareholder approval required
- Conducted over a 12-month period subject to market conditions
- Board's focus on disciplined capital management
- Reflects confidence in the company's strategy and growth prospects
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$25,227 |
Notification of cessation of securities - BXB
|
8 May 2026 8:27AM |
$22.600 |
$18.845 |
fallen by
16.62%
|
|
| Macquarie Group Limited (MQG) ORDINARY FULLY PAID |
Financials |
$95,266 |
Macquarie Group FY26 Shareholder Email
|
8 May 2026 8:27AM |
$241.870 |
$249.950 |
risen by
3.34%
|
|
| Norwest Minerals Limited (NWM) ORDINARY FULLY PAID |
Materials |
$10 |
High Gold Recoveries Support Advancement of Bulgera
|
8 May 2026 8:26AM |
$0.012 |
$0.009 |
fallen by
25%
|
|
NWM - Price-sensitive ASX Announcement
Full Release
Key Points
- Orelogy Mining Consultants will lead the Bulgera Scoping Study in 2026.
- Norwest Minerals Limited has updated the Mineral Resource Estimate for Bulgera to 23.8 Mt @ 0.65 g/t gold for 501,000 ounces.
- The Bulgera Gold Project's new JORC 2012 compliant resource applies a 0.24g/t lower gold cut-off.
- Heap leach test work is focused on Bulgera's oxide and transition material.
- 71% of the near-surface oxide and transition material is in the 'Indicated' confidence category.
- Bulgera's historical and recent drilling supports the definition of a mineral resource under the 2012 JORC code.
- Environmental approvals strategy for Bulgera is being prepared by MBS Environmental Consultants.
- The Bulgera Trend is a broad mineralised shear zone on the western side of the Bulgera Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,245 |
Update - Notification of buy-back - AFI
|
8 May 2026 8:26AM |
$6.610 |
$6.650 |
risen by
0.61%
|
|
| AMP Limited (AMP) ORDINARY FULLY PAID |
Financials |
$3,944 |
Update - Notification of buy-back - AMP
|
8 May 2026 8:25AM |
$1.525 |
$1.595 |
risen by
4.59%
|
|
| Murray Cod Australia Limited (MCA) ORDINARY FULLY PAID |
Consumer Staple |
$36 |
Retail Entitlement Offer Booklet
|
8 May 2026 8:25AM |
$0.140 |
$0.145 |
risen by
3.57%
|
|
MCA - Price-sensitive ASX Announcement
Full Release
Key Points
- Murray Cod Australia Limited (MCA) is conducting a 1 for 1 accelerated non-renounceable entitlement offer to raise approximately $18.6 million.
- The issue price for new shares is set at $0.15 per share.
- The Retail Entitlement Offer closes on 20 May 2026.
- The Entitlement Offer is fully underwritten by Ord Minnett Limited and Stralis Capital Partners Pty Ltd.
- The funds will be used for working capital, expanding processing capacity, restructuring costs, and offer expenses.
- MCA has a biomass of 3,700 tonnes valued at $78.3 million, with different size grades for commercial sale.
- MCA is expanding its market through partnerships with distributors and retailers like Woolworths and Coles.
- Biomass growth has been supported by improved feeding practices and infrastructure expansion.
- The company aims to focus on domestic market growth over the next 12-18 months while exploring export opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$278 |
Update - Notification of buy-back - AMH
|
8 May 2026 8:24AM |
$0.910 |
$0.885 |
fallen by
2.75%
|
|
| Australian Unity Office Property Fund (AOF) ORDINARY UNITS FULLY PAID |
Real Estate |
- |
Chairman Address Unitholder Meeting
|
8 May 2026 8:24AM |
$0.360 |
$0.365 |
risen by
1.39%
|
|
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$657 |
AGM Presentation Slides
|
8 May 2026 8:23AM |
$1.900 |
$1.860 |
fallen by
2.11%
|
|
| Macquarie Group Limited (MQG) ORDINARY FULLY PAID |
Financials |
$95,266 |
Macquarie Group Appendix 4G
|
8 May 2026 8:23AM |
$241.870 |
$249.950 |
risen by
3.34%
|
|
| Macquarie Group Limited (MQG) ORDINARY FULLY PAID |
Financials |
$95,266 |
Macquarie Group FY26 Management Discussion and Analysis
|
8 May 2026 8:23AM |
$241.870 |
$249.950 |
risen by
3.34%
|
|
MQG - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit increased by 30% to $A4,847 million.
- Return on equity improved to 14.0%.
- Net operating income grew by 13% to $A19,477 million.
- Macquarie Asset Management's performance boosted by increased fees.
- Macquarie Capital benefited from higher investment income.
- Operating expenses rose by 5% due to technology investments.
- Robust capital adequacy framework maintained.
- Diversified income streams bolstered revenue.
- Funding sources expanded to enhance stability.
- Focus on technology and infrastructure for growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IPH Limited (IPH) ORDINARY FULLY PAID |
Industrials |
$1,024 |
Update - Notification of buy-back - IPH
|
8 May 2026 8:22AM |
$3.830 |
$3.995 |
risen by
4.31%
|
|
| Macquarie Group Limited (MQG) ORDINARY FULLY PAID |
Financials |
$95,266 |
Macquarie Group FY26 Presentation
|
8 May 2026 8:22AM |
$241.870 |
$249.950 |
risen by
3.34%
|
|
MQG - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit rose by 30% to $4.8 billion in FY26.
- Commodities and Global Markets income increased by 20%.
- Significant growth in home loans and BFS deposits despite lower margins.
- Higher investment income driven by asset sales and market movements.
- Increased operating expenses due to investments and transaction costs.
- Strategic focus on diversification and global expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$657 |
Chair's Address for AGM
|
8 May 2026 8:22AM |
$1.900 |
$1.860 |
fallen by
2.11%
|
|
| Macquarie Group Limited (MQG) ORDINARY FULLY PAID |
Financials |
$95,266 |
Macquarie Group FY26 Media Release
|
8 May 2026 8:22AM |
$241.870 |
$249.950 |
risen by
3.34%
|
|
MQG - Price-sensitive ASX Announcement
Full Release
Key Points
- FY26 net profit was $A4,847 million, up 30% on FY25.
- The 2H26 net profit of $A3,192 million marked a record half-year result.
- Net operating income increased by 13% to $A19,477 million.
- International income accounted for 68% of total income.
- An income tax expense of $A1,860 million was recorded, with an effective tax rate of 27.6%.
- Macquarie Asset Management contributed $A2,602 million in net profit.
- Banking and Financial Services saw a 17% increase in net profit contribution.
- Commodities and Global Markets delivered a 49% increase in net profit contribution.
- Macquarie Capital's net profit contribution rose by 43%.
- Total deposits reached $A221.5 billion, up 25% from the previous year.
- The final ordinary dividend for FY26 was $A4.20 per share.
- No further purchases are expected in the on-market share buyback.
- Jillian Broadbent will step down from the Board in December 2026.
- Macquarie maintains a cautious outlook with a strong balance sheet and risk management framework.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regener8 Resources NL (R8R) ORDINARY FULLY PAID |
Materials |
$8 |
Entitlement Offer Closure
|
8 May 2026 8:21AM |
$0.120 |
$0.125 |
risen by
4.17%
|
|
| Ramsay Health Care Limited (RHC) ORDINARY FULLY PAID |
Health Care |
$9,178 |
RAMSAY SANTE - Results for 9 months to 31 March 2026
|
8 May 2026 8:21AM |
$37.610 |
$39.760 |
risen by
5.72%
|
|